Expression of serine protease SNC19/matriptase and its inhibitor hepatocyte growth factor activator inhibitor type 1 in normal and malignant tissues of gastrointestinal tract

Lei Zeng, Jiang Cao, Xing Zhang

Lei Zeng, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang Province, China
Jiang Cao, Xing Zhang, Clinical Research Institute, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou 310016, Zhejiang Province, China
Supported by the National Natural Science Foundation of China, No. 30271459; the Natural Science Foundation of Zhejiang Province, No. 300466
Correspondence to: Dr. Jiang Cao, Clinical Research Institute, Sir Run Run Shaw Hospital, Zhejiang University, 3 East Qingchun Road, Hangzhou 310016, Zhejiang Province, China. caoj@zju.edu.cn
Telephone: +86-571-86006336  Fax: +86-571-86960497
Received: 2005-03-01  Accepted: 2005-04-18

Abstract

AIM: To provide the expression profile of serine protease SNC19/matriptase and its inhibitor hepatocyte growth factor activator inhibitor type 1 (HAI-1) in normal and malignant tissues of gastrointestinal tract at mRNA level for further study on their correlations with tumor progression and metastasis.

METHODS: Total RNAs were prepared from 37 samples of colorectal cancer tissues, 40 samples of gastric cancer tissues, and their adjacent normal tissues. The expression of SNC19/matriptase and HAI-1 in these samples was detected by real-time fluorescent quantitative PCR using glyceraldehyde-3-phosphate dehydrogenase as internal standard, and the clinical significance for the correlation with clinicopathological parameters was evaluated.

RESULTS: In gastric cancer tissues the expression of HAI-1 and SNC19/matriptase was significantly lower than that in the corresponding adjacent normal tissues (Z = -3.280, P = 0.006; Z = -4.651, P = 0.000). HAI-1:SNC19/matriptase ratio showed no difference between normal and malignant tissues (P>0.05). Analysis of clinicopathological parameters showed decreased expression of HAI-1 and HAI-1:SNC19/matriptase ratio associated with stage III/IV gastric tumors as compared to stage I/II ones (Z = -2.140, P = 0.031; Z = -2.155, P = 0.031), and with lymph node-positive gastric cancer tissues as compared to lymph node-negative ones (Z = -2.081, P = 0.036; Z = -2.686, P = 0.006). The expression of SNC19/matriptase had no relationship with stages and lymph node metastasis (P>0.05). The expression of HAI-1 and HAI-1:SNC19/matriptase ratio increased in well-differentiated gastric cancer tissues, but there was no statistical significance (P>0.05). The difference of SNC19/matriptase expression was not significant in gastric cancer tissues of different histological differentiation status (P>0.05). In colorectal cancer tissues, the expression of HAI-1 and SNC19/matriptase was also markedly lower than that in their adjacent normal tissues (Z = -3.100, P = 0.002; Z = -2.731, P = 0.006), whereas HAI-1:SNC19/matriptase ratio showed no difference. Decreased expression of HAI-1 was associated with increased invasive depth and lymph node metastasis, but there was no statistical significance (P>0.05). The difference of SNC19/matriptase expression and HAI-1: SNC19/matriptase ratio was not significant in different stages and different lymph node metastasis status (P>0.05). The expression of SNC19/matriptase, HAI-1 or HAI-1: SNC19/matriptase ratio showed no difference in colorectal cancer tissues of different histological differentiation status (P>0.05).

CONCLUSION: The expressions of SNC19/matriptase and its inhibitor HAI-1 are decreased in gastrointestinal cancer tissues compared to their normal counterparts, and the decreased expression of HAI-1 may correlate with invasion and lymph node metastasis. The possible mechanisms involved need to be further investigated.

© 2005 The WJG Press and Elsevier Inc. All rights reserved.

Key words: Matriptase; Hepatocyte growth factor activator inhibitor type 1; Expression; Metastasis

Zeng L, Cao J, Zhang X. Expression of serine protease SNC19/matriptase and its inhibitor hepatocyte growth factor activator inhibitor type 1 in normal and malignant tissues of gastrointestinal tract. World J Gastroenterol 2005; 11(39): 6202-6207 http://www.wjgnet.com/1007-9327/11/6202.asp

INTRODUCTION

Hepatocyte growth factor (HGF), also known as scatter factor (SF) [1], is a pleiotropic factor which functions as a mitogen, a morphogen, and a motogen for a variety of cells bearing Met receptor tyrosine kinase, particularly for epithelial cells and vascular endothelial cells [2-4]. To date, a significant body of evidence is accumulating in favor of the notion that HGF/SF and Met play an important role in tumorigenesis, invasiveness, differentiation and angiogenesis of tumor cells [5-8]. HGF/SF is secreted by mesenchymal cells as an inactive precursor form, which lacks biological activity. The proteolytic activation of a single-chain precursor
form to a two-chain heterodimeric active form is a critical stepping limit in the HGF/SF-induced Met signaling pathway. Five proteases have been supposed to be responsible for the activation of HGF/SF: hepatocyte growth factor activator (HGF-A), which exhibits the most potent activity, urokinase-type plasminogen activator (uPA), tissue-type plasminogen activator, blood coagulation factor XIIa, and SNC19/matriptase. SNC19 initially identified was first found in T47-D human breast cancer cells. In addition to activation of HGF/SF, SNC19/matriptase can also degrade extracellular matrix (ECM), and activate another ECM-degrading protease uPA which is involved in tumor invasion. SNC19/matriptase contributes to ECM degradation, cellular motility, epithelial migration and turnover, tissue remodeling, and it is supposed to be involved in tumor cell invasion and metastasis.

Hepatocyte growth factor activator inhibitor type 1 (HAI-1) is a Kunitz-type serine protease inhibitor which was initially purified from the conditioned medium of a human MKN45 stomach carcinoma cell line in 1997. HAI-1 can specifically inhibit serine proteases HGFα and SNC19/matriptase, and they both are activators of HGF/SF. Although it is supposed that HAI-1 and SNC19/matriptase may be involved in tumorigenesis, progression, and metastasis, more evidence is needed to draw a definite conclusion. This paper presents new evidence for the expression of HAI-1 and SNC19/matriptase in normal and malignant tissues of gastrointestinal tract at mRNA level, and their correlations with tumor progression and metastasis.

MATERIALS AND METHODS

Patients and tissues
A total of 40 samples from gastric cancer patients (median age, 58.95±12.43 years; range, 29-82 years; 28 men and 12 women) and 37 samples from colorectal cancer patients (median age, 61.64±13.54 years; range, 32-89 years; 13 men and 24 women), after surgical treatment in Second Affiliated Hospital, Zhejiang University College of Medicine, were studied retrospectively. The stage of gastric cancer was classified according to UICC guidelines (1985). Dukes’ stage of colorectal cancer was classified according to the diagnosis and treatment criteria for common malignancy in China (1990). Tumor location, tumor histology, and histological grade were determined by pathological examination.

Specimens and RNA preparation
Cancer tissues and their adjacent normal tissues at least 15 cm away from cancer were collected immediately after excision, snap-frozen in liquid nitrogen, and stored at -80°C for RNA extraction. Total RNAs were extracted from the tissue samples by TRIzol reagent (Gibco BRL Co., USA) according to the manufacturer’s instructions in 0.1% RNase-free DEPC H₂O. RNA samples were quantified by ultraviolet spectrophotometry (Hewlett-Packard Co., USA).

Primers and probes
Primers and probes used for real-time fluorescent quantitative PCR were designed with the software PrimerExpress (Applied Biosystems Inc., USA). To avoid possible amplification of contaminating genomic DNA, primers were designed, so that each PCR product covered at least one intron. The sequences of primers and probes are listed in Table 1.

| Target gene (amplicon size) | Sequence (5’-3’) |
|-----------------------------|------------------|
| HAI-1 (151 bp)              | Upstream primer: TGG CCA AGA GCA GCA GCAG TGCC AGA GAG TAC GCA AAT GCC AGA GGG GCA CAG TGG AGA TGG C - TAMRA |
|                            | Downstream primer: GGC TAC CAC CAC CAC AAT GCC AGA GGG GCA CAG TGG AGA TGG C - TAMRA |
| SNC19/matriptase (168 bp)  | Upstream primer: GGG ACA CAC CCA GTA TGG AGG |
|                            | Downstream primer: CCG GAA TCA CCC TGC CAG GA |
| GAPDH (151 bp)             | Upstream primer: CTG ACC CCT GCC CAA AGA GAG GGT AGA TCC |
|                            | Downstream primer: GAT GTT CTT AGG GAG CCC CCA TAC AAT GCT GCC ACC CAG AAG A - TAMRA |

PCR standards
Plasmids containing HAI-1, SNC19/matriptase or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNAs were constructed and maintained in our laboratory. Purified plasmid DNAs were quantified by absorbance at 260 nm and serially diluted as PCR standards.

Real-time RT-PCR
Two micrograms of total RNA was used in a 25 μL reverse transcription reaction system containing oligo (dT)₁₅ and M-MLV reverse transcriptase (Promega Co., USA). For real-time PCR, the cDNA samples were brought to a final concentration of 50 mmol/L KCl, 10 mmol/L Tris-HCl (pH 9.0), 1.5 mmol/L MgCl₂, 0.1% Triton-X 100, 200 μmol/L dNTPs, 0.2 μmol/L each primer, 0.1 μmol/L probe, and 5 U/μL Taq DNA polymerase (Promega Co., USA). The reactions were carried out under pre-optimized conditions. Samples were amplified with a hold at 95°C for 5 min, followed by 40 cycles of denaturation at 95°C for 20 s, annealing at 60°C for 20 s and extension at 72°C for 20 s in the ABI Prism 7700 sequence detector (Perkin Elmer Co., USA). Serially diluted standard specimens with the concentration of 10⁸-10¹⁰ copies/mL were used to plot the standard curve. No template control and no reverse transcription control were included; 2% agarose gel electrophoresis was used in optimizing procedure.

Statistical analysis
All statistical analyses were done by the SPSS 11.0 software package. Non-parametric data were analyzed with Wilcoxon, Mann-Whitney, and Kruskal-Wallis rank sum tests to evaluate the association between SNC19/matriptase and HAI-1 mRNA expression and clinicopathological parameters. M(β₀) was computed as summary statistics.

Zeng L et al. Expression of SNC19/matriptase and HAI-1 in gastrointestinal cancer 6203
RESULTS

Real-time RT-PCR of SNC19/matriptase and HAI-1

Real-time fluorescent quantitative RT-PCR was performed to determine the expression of SNC19/matriptase and HAI-1 at mRNA level using GAPDH as internal control. Figure 1 shows the detection and plotting of the GAPDH standard curve. The PCR products were subjected to 2% agarose gel electrophoresis in optimized procedure, as shown in Figure 2. The products were specific, with anticipated sizes confirmed by DNA sequencing.

Expression of HAI-1 and SNC19/matriptase in normal and malignant tissues of gastrointestinal tract and correlation with clinicopathological parameters

The mRNA copy numbers of HAI-1, SNC19/matriptase and internal control GAPDH in each of normal and malignant tissues of gastrointestinal tract were detected by real-time fluorescent quantitative RT-PCR technique. The ratios of HAI-1:GAPDH and SNC19/matriptase:GAPDH were used as the relative expression level of HAI-1 and SNC19/matriptase, respectively. As shown in Table 2, the expression of HAI-1 and SNC19/matriptase in both gastric and colorectal cancer tissues was markedly lower than that in their adjacent normal tissues (P<0.01), while HAI-1:SNC19/matriptase ratio showed no significant difference between normal and malignant tissues of gastrointestinal tract (P>0.05).

The correlations between the expression of HAI-1 and SNC19/matriptase and clinicopathological parameters were evaluated (Tables 3 and 4). In gastric cancer tissues (Table 3), decreased expression of HAI-1 and HAI-1:SNC19/matriptase ratio were associated with stage III/IV cancer tissues compared to stage I/II ones (Z=-2.140, P=0.031; Z=-2.155, P=0.031). The expression of SNC19/matriptase had no relationship with clinical stages (P>0.05). The expression of HAI-1 and HAI-1:SNC19/matriptase ratio in lymph node-positive cancer tissues were lower than those in lymph node-negative ones (Z=-2.081, P=0.036; Z=-2.686, P=0.006). The expression of HAI-1 and HAI-1:SNC19/matriptase ratio increased in well-differentiated gastric cancer tissues, but there was no statistical significance (P>0.05). The differences of SNC19/matriptase were not significant in gastric cancer tissues with different histological differentiation status (P>0.05). In colorectal cancer tissues, the expression of HAI-1 was lower in Dukes’ C/D cancer tissues than in Dukes’ B ones. HAI-1 expression in lymph node-positive cancer tissues was lower than that in lymph node-negative ones. Decreased expression of HAI-1 was associated with increased invasive depth and lymph node metastasis, although there was no statistical significance (P>0.05). The differences of SNC19/matriptase expression and HAI-1:SNC19/matriptase ratio in lymph node-positive cancer tissues were lower than those in lymph node-negative ones (P=0.036; Z=-2.686, P=0.006). However, the differences of SNC19/matriptase expression and HAI-1:SNC19/matriptase ratio were not significant in different stages and different lymph node metastasis status (P>0.05). All the expression of HAI-1 and SNC19/matriptase and their ratio showed no statistical significance in different histological differentiation status (P>0.05). In gastrointestinal cancers, the expression of HAI-1 and SNC19/matriptase and HAI-1:SNC19/matriptase ratio showed no difference in patients of different ages, genders, location of tumors, and histological types (P>0.05).

Table 2 Expression of HAI-1 and SNC19/matriptase in normal and malignant tissues of gastrointestinal tract [M(±QR)]

|          | Gastric tissues | Colorectal tissues |
|----------|-----------------|--------------------|
|          | HAI-1           | SNC19              | HAI-1:SNC19        | HAI-1           | SNC19              | HAI-1:SNC19        |
| Normal   | 0.012 (0.021)   | 0.010 (0.014)     | 1.420 (1.662)      | 0.014 (0.022)   | 0.010 (0.014)     | 0.971 (1.415)      |
| Malignant| 0.005 (0.013)   | 0.004 (0.005)     | 1.365 (1.820)      | 0.009 (0.007)   | 0.005 (0.005)     | 1.520 (1.215)      |
| Z        | -3.280          | -4.651             | -0.121             | -3.100          | -2.731             | -0.999             |
| P        | 0.001           | 0.000              | 0.904              | 0.002           | 0.006              | 0.318              |
### Table 3 Correlation between HAI-1 and SNC19/matriptase expression and clinicopathology in gastric cancer tissues \( [M(Q_{0})] \)

| Age (yr) | Patients | HAI-1 | SNC19 | HAI-1:SNC19 |
|----------|----------|-------|-------|-------------|
| <40 yr   | 3        | 0.004 (0.003) | 0.005 (0.002) | 0.778 (0.349) |
| 40-60 yr | 10       | 0.007 (0.012) | 0.005 (0.003) | 0.798 (1.096) |
| >60 yr   | 23       | 0.009 (0.104) | 0.005 (0.005) | 0.677 (0.459) |
| Unknown  | 1        | 0.005 (0.110) | 0.005 (0.004) | 1.355 (1.386) |

| Gender   | N factor | Histological grade | N0 | N1/N2 | I/I | II/III/IV |
|----------|----------|--------------------|----|-------|-----|-----------|
| Men      | 12       | 0.017 (0.032)①  | 0.004 (0.005) | 2.280 (0.148)① |
| Women    | 28       | 0.004 (0.005) | 0.004 (0.005) | 1.080 (1.489) |
| Location | Cardia   | 7                  | 0.005 (0.004) | 0.003 (0.002) | 1.430 (0.210) |
|          | Body     | 7                  | 0.007 (0.023) | 0.004 (0.005) | 2.620 (2.846) |
|          | Pylorus  | 17                 | 0.005 (0.015) | 0.005 (0.005) | 1.080 (1.631) |
|          | Unknown  | 9                  | 0.005 (0.110) | 0.003 (0.004) | 1.220 (1.219) |

### Table 4 Correlation between HAI-1 and SNC19/matriptase expression and clinicopathology in colorectal cancer tissues \( [M(Q_{0})] \)

| Age (yr) | Patients | HAI-1 | SNC19 | HAI-1:SNC19 |
|----------|----------|-------|-------|-------------|
| <40 yr   | 3        | 0.004 (0.003) | 0.005 (0.002) | 0.778 (0.349) |
| 40-60 yr | 10       | 0.007 (0.012) | 0.005 (0.003) | 0.798 (1.096) |
| >60 yr   | 23       | 0.009 (0.104) | 0.005 (0.005) | 0.677 (0.459) |
| Unknown  | 1        | 0.005 (0.110) | 0.005 (0.004) | 1.355 (1.386) |

| Gender   | N factor | Histological grade | N0 | N1/N2 | Dukes’ stage |
|----------|----------|--------------------|----|-------|--------------|
| Men      | 12       | 0.017 (0.032)①  | 0.004 (0.005) | 2.280 (0.148)① |
| Women    | 19       | 0.007 (0.005) | 0.005 (0.004) | 1.480 (0.980) |
| Location | Cardia   | 7                  | 0.011 (0.015) | 0.004 (0.008) | 1.790 (3.860) |
|          | Body     | 10                 | 0.010 (0.016) | 0.005 (0.013) | 1.290 (1.243) |
|          | C/D     | 20                 | 0.006 (0.006) | 0.005 (0.005) | 1.385 (0.955) |

### Discussion

The inhibitors of serine proteases are important regulators of enzyme activities. They are classified into at least 10 families\[29\]. Among them, serpins (serine protease inhibitor) such as Kunitz-type inhibitors are correlated with suppression of tumor invasion\[28\].

Serine protease SNC19/matriptase is a newly characterized ECM-degrading protease, which may also function as an activator for HGF/SF and other proteases. HAI-1, the cognate Kunitz type inhibitor of SNC19/matriptase, was first found in the stomach carcinoma cell line. Although the expression of HAI-1 has been studied in some types of cancer, the expression profile in normal and malignant gastric tissues is still absent.

As was found in epithelial ovarian cancers that all HAI-1-positive tumors are also SNC19/matriptase positive\(18\), the imbalance between the protease and the inhibitor may play an important role in the development of tumors. In this study, HAI-1 and SNC19/matriptase showed a remarkable decrease in cancer tissues compared to their adjacent normal tissues in gastrointestinal tract, but the ratio of HAI-1: SNC19/matriptase showed no significant difference between normal and malignant gastrointestinal tissues. Whether the ratio is critical to tumor development or progression needs to be further investigated. Since a novel function of the integral membrane Kunitz-type inhibitor in the regulation of pericellular protease activity has been suggested, HAI-1 may act not only as an inhibitor but also as a reservoir of this enzyme on cell surface\[23,20\]. With this possibility and other lines of evidence, the situation in cancer may be more complicated. HAI-1 has a strong affinity for both HGFA and SNC19/matriptase to form a protease/inhibitor complex and its specific Kunitz domains are responsible for the inhibitory activity\[27\]. It was reported that HAI-1 may participate in the activation of SNC19/matriptase through their low-density lipoprotein receptor class A domains interacting with each other, and HAI-1-mediated activation and inhibition of SNC19/ matriptase occur in human mammary epithelial cells\[28\]. At the same time, HAI-1 not only inhibits the activity of SNC19/matriptase but also prevents it from being hydrolyzed by other proteases\[29\]. It was reported that decreased immunoreactivity of membrane-form HAI-1 and enhanced ectodomain shedding of HAI-1 are found in colorectal adenocarcinoma cells\[30\]. There might be a more complicated interaction between HAI-1 and SNC19/matriptase rather than simple activity inhibition. In breast cancer cells, SNC19/matriptase is detected mainly as an uncomplexed form, whereas in human milk a complex containing matriptase and HAI-1 is detectable\[30\]. The active form of SNC19/matriptase may release from HAI-1 fragment into extracellular milieu, thus playing a role in tumor cells as ectodomain shedding of HAI-1 enhances, which may provide SNC19/matriptase opportunities to actively down-stream biological factors.

HAI-1 expression and HAI-1: SNC19/matriptase ratio decrease in gastric cancer tissues where invasion and lymph node metastasis occur. HAI-1 may play a role in progression and metastasis of gastric cancer by inhibiting HGF. SNC19/ matriptase showed no significant difference in invasive tumors in this study. Lower ratio of HAI-1:SNC19/
matriptase in stage III/IV cancers compared to stage I/II ones may be due to the down-regulated expression of HAI-1. The expression of HAI-1 tends to increase in well-differentiated gastric cancer tissues. It was reported that the expression of HAI-1 increases as the histological grade decreases in hepatocellular carcinoma [31], and decreases in poorly differentiated breast tumors [32]. HAI-1 displays different patterns of expression in different tissues [33].

In colorectal cancer tissues, HAI-1 expression is inverse correlated tumor invasion and lymph node metastasis. In our study, the expression of HAI-1, SNC19/matriptase and their ratio did not show differences in colorectal cancer tissues with different differentiation status, but the expression of HAI-1 seemed to be related to histological grades. Further analysis regarding the patients’ age, gender, location, and histological type of tumor showed no correlation with HAI-1 expression.

In conclusion, both SNC19/matriptase and HAI-1 are downregulated in gastrointestinal cancer tissues, and the underlying mechanisms need to be extensively investigated. A larger scale study both in case number and disease spectrum needs to be carried out to elucidate the exact role of SNC19/matriptase and HAI-1 in tumor development and progression.

REFERENCES

1. Weidner KM, Arakaki N, Hartmann G, Vanderkreekove J, Weingart S, Rieder H, Fonatsch C, Tsubouchi H, Hishida T, Daikiuhara Y. Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc Natl Acad Sci USA 1991; 88: 7001-7005

2. Naldiini I, Weidner KM, Vigna E, Gaudino G, Bardelli A, Ponzetto C, Narsimhan RP, Hartmann G, Zarnegar R, Michalopoulos GK. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EnBio J 1991; 10: 2867-2878

3. Boros P, Miller CM. Hepatocyte growth factor: a multifunctional cytokine. Lancet 1995; 345: 293-295

4. Matsumoto K, Nakamura T. Emerging multipotent aspects of hepatocyte growth factor. J Biochem 1996; 119: 591-600

5. Bellussi S, Moens G, Gaudino G, Comoglio P, Nakamura T, Thiery JP, Jouanneau J. Creation of an hepatocyte growth factor/scatter factor autocrine loop in carcinoma cells induces invasive properties associated with increased tumorigenicity. Oncogene 1994; 9: 1091-1099

6. Nakamura T, Matsumoto K, Kiiritoshi A, Tano Y. Induction of hepatocyte growth factor in fibroblasts by tumor-derived factors affects invasive growth of tumor cells: in vitro analysis of tumor-stromal interactions. Cancer Res 1997; 57: 3305-3313

7. Gak E, Taylor WG, Chan AM, Rubin JS. Processing of hepatocyte growth factor to the heterodimeric form is required for biological activity. FEBS Lett 1992; 311: 17-21

8. Shimomura T, Miyazawa K, Komiyama Y, Hiraoka H, Naka D, Morimoto Y, Kitamura N. Activation of hepatocyte growth factor by two homologous proteases, blood-coagulation factor XIIa and hepatocyte growth factor activator. Eur J Biochem 1995; 229: 257-261

9. Mars WM, Zarnegar R, Michalopoulos GK. Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA. Am J Pathol 1993; 143: 949-958

10. Cao J, Zheng S, Zheng L, Cai X, Zhang Y, Geng L, Fang Y. A novel serine protease SNC19 associated with human colorectal cancer. Chin Med J 2001; 114: 726-730

11. Lee SL, Dickson RB, Lin CY. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 2000; 275: 36720-36725

12. Cao J, Cai X, Zheng L, Geng L, Shi Z, Pao CC, Zheng S. Characterization of colorectal-cancer-related cDNA clones obtained by subtractive hybridization screening. J Cancer Res Clin Oncol 1997; 123: 447-451

13. Lin CY, Anders J, Johnson M, Sang QA, Dickson RB. Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity. J Biol Chem 1999; 274: 18231-18236

14. Satomi S, Yamasaki Y, Tsubouchi H, Iwanaga T, Fushiki T. A role for membrane-type serine protease (MT-SP1) in intestinal epithelial turnover. Biochem Biophys Res Commun 2001; 287: 995-1002

15. Migliani P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993; 73: 161-195

16. Oberst MD, Johnson MD, Dickson RB, Lin CY, Singh B, Stewart M, Williams A, al-Nafussi A, Smyth JF, Gabra H, Sellar CC. Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters. Clin Cancer Res 2002; 8: 1101-1107

17. Shimomura T, Denda K, Kitamura A, Kawaguchi T, Kito M, Kondo J, Kagaya S, Qin L, Takata H, Miyazawa K, Kitamura N. Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor. J Biol Chem 1997; 272: 6370-6376

18. Lin CY, Anders J, Johnson M, Dickson RB. Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. J Biol Chem 1999; 274: 18237-18242

19. Kataoka H, Miyata S, Uchinokura S, Itoh H. Roles of hepatocyte growth factor (HGF) activator and HGF activator inhibitor in the pericellular activation of HGF/scatter factor. Cancer Metastasis Rev 2003; 22: 223-236

20. Oberst M, Anders J, Xie B, Singh B, Ossandon M, Johnson M, Dickson RB, Lin CY. Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am J Pathol 2001; 158: 1301-1311

21. Johnson MD, Oberst MD, Lin CY, Dickson RB. Possible role of matriptase in the diagnosis of ovarian cancer. Expert Rev Mol Diagn 2003; 3: 331-338

22. Kang JY, Dolloff-Filho M, Ocal JT, Singh B, Lin CY, Dickson RB, Rimm DL, Camp RL. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res 2003; 63: 1101-1105

23. Laskowski M Jr, Kato I. Protein inhibitors of proteinases. Anna Rev Biochem 1980; 49: 593-626

24. Kobayashi H, Shinohara H, Takeuchi K, Itoh M, Fujie M, Saitoh T, Terao T. Inhibition of the soluble and the tumor cell receptor-bound plasmin by urinary trypsin inhibitor and subsequent effects on tumor cell invasion and metastasis. Cancer Res 1994; 54: 844-849

25. Kataoka H, Shimomura T, Kawaguchi T, Hamasuna R, Itoh H, Kitamura N, Miyazawa K, Koono M. Hepatocyte growth factor activator inhibitor type 1 is a specific cell surface binding protein of hepatocyte growth factor activator (HGF/A) and regulates HGF/A activity in the pericellular microenvironment. J Biol Chem 2000; 275: 40453-40462

26. Kataoka H, Itoh H, Hamasuna R, Meng JY, Koono M. Pericellular activation of hepatocyte growth factor/scatter factor (HGF/SF) in colorectal carcinomas: roles of HGF activator (HGF/A) and HGF/A inhibitor type 1 (HAI-1). Hum Cell 2001; 14: 83-93

27. Denda K, Shimomura T, Kawaguchi T, Miyazawa K, Kitamura N. Functional characterization of Kunitz domains in hepatocyte growth factor activator inhibitor type 1. J Biol Chem 2002; 277: 14053-14059
28 Lee MS, Kiyomiya KI, Benaud C, Dickson RB, Lin CY. Simultaneous activation and HAI-1-mediated inhibition of matriptase induced at activation foci in human mammary epithelial cells. *Am J Physiol Cell Physiol* 2004; 288: C932-C941

29 Oberst MD, Williams CA, Dickson RB, Johnson MD, Lin CY. The activation of matriptase requires its noncatalytic domains, serine protease domain, and its cognate inhibitor. *J Biol Chem* 2003; 278: 26773-26779

30 Nagaike K, Kohama K, Uchiyama S, Tanaka H, Chijiiwa K, Itoh H, Kataoka H. Paradoxically enhanced immunoreactivity of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in cancer cells at the invasion front. *Cancer Sci* 2004; 95: 728-735

31 Nagata K, Hirono S, Ido A, Kataoka H, Morisuchi A, Shimomura T, Hori T, Hayashi K, Koono M, Kitamura N, Tsubouchi H. Expression of hepatocyte growth factor activator and hepatocyte growth factor activator inhibitor type 1 in human hepatocellular carcinoma. *Biochem Biophys Res Commun* 2001; 289: 205-211

32 Parr C, Watkins G, Mansel RE, Jiang WG. The hepatocyte growth factor regulatory factors in human breast cancer. *Clin Cancer Res* 2004; 10: 202-211

33 Parr C, Jiang WG. Expression of hepatocyte growth factor/scatter factor, its activator, inhibitors and the c-Met receptor in human cancer cells. *Int J Oncol* 2001; 19: 857-863